Preclinical efficacy study results for the first Russian humanised monoclonal antibody OM-RCA-01, indicated for treatment of renal cell carcinoma, were presented at the New Technologies session of the Congress of the American Society of Clinical Oncology (ASCO) at the beginning of June in Chicago. This antibody is being developed by OncoMax, a Skolkovo resident with investments from Maxwell Biotech Venture Fund, founded with the participation of RVC OJSC and RVC Seed Fund.
ASCO Congress is the world largest event on clinical oncology which annually gathers more than 30 thousand specialists interested in the latest achievements in the field of cancer treatment. In his report the Chief Scientific Adviser of OncoMax, Dr. I.V. Tsimafeyeu, voiced the results of preclinical efficacy and safety studies of the developed medicine OM-RCA-01, these results were also presented at the 27th Annual Congress of the European Association of Urology (Paris, February 2012) and at the Annual Congress of the American Association for Cancer Research (AACR) 2012 (Chicago, April 2012).
“The interest to targeted medicines for cancer treatment is very high, thus the results of OM-RCA-01 development presented at the congress have received the most positive responses. Clinical oncologists specializing on renal cancer are interested in the introduction of this new medicine on the market as soon as possible”, Dr. I.V. Tsimafeyeu commented his participation in the Congress.